Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. Gilead Sciences, Inc. Transaction History

Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P.

$467 Million
Q2 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $227,346 - $291,198	-3,630 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $82,878 - $91,164	-1,345 Reduced 27.04%	3,630 $236,000
Q3 2019 Nov 14, 2019	SELL	$62.51 - $69.0 $26,254 - $28,980	-420 Reduced 7.78%	4,975 $315,000
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $2,784 - $3,122	-45 Reduced 0.83%	5,395 $364,000
Q1 2019 May 15, 2019	SELL	$62.53 - $70.05 $40,331 - $45,182	-645 Reduced 10.6%	5,440 $354,000
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $82,334 - $107,440	-1,360 Reduced 18.27%	6,085 $381,000
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $12,830 - $14,205	-180 Reduced 2.36%	7,445 $575,000
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $3,568 - $4,162	-55 Reduced 0.72%	7,625 $540,000
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $7,284 - $8,880	100 Added 1.32%	7,680 $579,000
Q4 2017 Feb 14, 2018	SELL	$71.15 - $83.52 $7,115 - $8,352	-100 Reduced 1.3%	7,580 $543,000
Q3 2017 Nov 09, 2017	BUY	$72.11 - $85.47 $553,804 - $656,409	7,680	7,680 $622,000

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

Black Rock Inc. New York, NY

121M
Shares

$10.1 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$9.64 Billion
0.15% of portfolio
Capital World Investors Los Angeles, CA

76.2M
Shares

$6.38 Billion
0.88% of portfolio
Capital Research Global Investors Los Angeles, CA

60.4M
Shares

$5.05 Billion
0.94% of portfolio
State Street Corp Boston, MA

59.3M
Shares

$4.96 Billion
0.18% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Holt Capital Advisors, L.L.C. Dba Holt Capital Partners, L.P. with notifications on news.

Account